TABLE 2.

Risk Factors for Patients with Significant (>10%) Absolute Change in eGFR After Treatment with ¹⁷⁷Lu-DOTATATE

Patient no.	Age (y)	Treatment cycles (n)	Cumulative administered dose (MBq)	Risk factors for renal toxicity	Baseline eGFR (mL/min/1.73 m²)	Last recorded eGFR (mL/min/ 1.73 m²)	Follow-up (y)	Annual % eGFR loss
1	64	4	30,689	HTN, DM	43	36	2.16	7.55
2	49	4	30,291	—	49	39	2.68	5.48
3	70	4	30,000	Age > 65, HTN	48	41	1.66	8.78
4	46	2	15,200	Chemotherapy, ⁹⁰Y-PRRT	56	49	1.01	12.36
5	57	2	14,878	Age > 65,⁹⁰Y-PRRT	43	34	5.12	4.09
6	81	4	29,708	Age > 65, HTN	39	15^*	2.93	21.01
7	76	4	29,708	Age > 65, HTN	53	37	2.78	10.88
8	62	4	29,309	—	48	35	3.08	8.80
9	69	4	29,901	Age > 65, HTN, DM	49	44	4.66	2.19
10	73	4	28,791	Age > 65, chemotherapy	53	38	3.26	8.69
11	59	4	28,424	HTM, DM, chemotherapy	58	51	3.20	3.77
12	79	4	29,761	Age > 65	56	39	3.64	8.33
13	57	4	29,793	Chemotherapy	48	33	3.99	7.84
14	68	4	30,970	Age > 65, HTN, chemotherapy	51	44	2.28	6.02
15	67	4	29,690	Age > 65	58	52	3.38	3.06